Background <p>Antitumor immune responses induced by oncolytic immunotherapy (OI) are often followed by upregulation of programmed death-ligand 1 (PD-L1). As such, the combination of OI with blockade of the programmed cell death protein-1 (PD-1)/PD-L1 axis has demonstrated therapeutic activity in preclinical and clinical trials. The purpose of this study is to understand further the immune-mediated mechanism of interaction between oncolytic…
Effects of oncolytic immunotherapy with RP1 (vusolimogene oderparepvec) on immune cells mediate responsiveness to anti-PD-1 via STING-mediated interferon signaling
Journal for ImmunoTherapy of Cancer | | Roulstone, V., Kyula, J., Appleton, E., Bommareddy, P. K., Patrikeev, A., Jones, S., Kuncheria, L., Chan Wah Hak, C. M., Foo, S., Baldock, H., Wongariyapak, A., Leslie, I., Pickering, R., Zierhut, C., Smith, H. G., Mohan, N., Murano, C., Hubbard, L. C., Dean, I., Patin, E. C., Gkantalis, J., Mansfield, D., Pedersen, M., McLaughlin, M., Goicoechea, M., Layzell, S., Mannion, J., Fernando, W., Meier, P., Vile, R., Melcher, A., Coffin, R. S., Harrington, K. J.
Topics: immunotherapy, clinical-trials, research
Read the full article at Journal for ImmunoTherapy of Cancer